X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2441) 2441
cell line, tumor (1454) 1454
apoptosis (1418) 1418
cell cycle (1395) 1395
g1 phase cell cycle checkpoints - drug effects (1135) 1135
apoptosis - drug effects (1126) 1126
animals (1112) 1112
cell proliferation - drug effects (1037) 1037
oncology (877) 877
cancer (872) 872
g1 phase (809) 809
cell biology (721) 721
mice (713) 713
proteins (656) 656
expression (639) 639
antineoplastic agents - pharmacology (632) 632
female (623) 623
cell proliferation (617) 617
g1 phase - drug effects (595) 595
phosphorylation (560) 560
biochemistry & molecular biology (530) 530
kinases (505) 505
proliferation (453) 453
male (433) 433
flow cytometry (428) 428
growth (427) 427
activation (426) 426
signal transduction - drug effects (425) 425
signal transduction (411) 411
gene expression (410) 410
cell growth (391) 391
cell survival - drug effects (381) 381
inhibition (352) 352
cell cycle checkpoints - drug effects (339) 339
analysis (336) 336
dose-response relationship, drug (325) 325
research article (318) 318
research (309) 309
dna damage (305) 305
tumor suppressor protein p53 - metabolism (303) 303
p53 (287) 287
tumors (281) 281
cell cycle - drug effects (278) 278
multidisciplinary sciences (278) 278
biology (274) 274
pharmacology & pharmacy (272) 272
medicine (266) 266
g1 phase cell cycle checkpoints (265) 265
chemotherapy (262) 262
rna interference (262) 262
cell line (253) 253
mice, nude (248) 248
in-vitro (244) 244
cancer therapies (242) 242
xenograft model antitumor assays (241) 241
science (238) 238
deoxyribonucleic acid--dna (234) 234
breast cancer (229) 229
cytotoxicity (228) 228
cell cycle proteins - metabolism (224) 224
gene expression regulation, neoplastic (222) 222
resting phase, cell cycle - drug effects (220) 220
cyclin d1 (219) 219
cyclin d1 - metabolism (218) 218
down-regulation (214) 214
proto-oncogene proteins c-akt - metabolism (214) 214
health aspects (213) 213
cyclin-dependent kinase inhibitor p21 - metabolism (211) 211
blotting, western (205) 205
protein (205) 205
time factors (205) 205
cells, cultured (203) 203
metastasis (202) 202
cells (201) 201
care and treatment (200) 200
g1 phase cell cycle checkpoints - genetics (193) 193
genetic aspects (193) 193
mice, inbred balb c (191) 191
s phase (191) 191
reactive oxygen species - metabolism (190) 190
dna (189) 189
cell death (188) 188
cancer cells (180) 180
studies (180) 180
rats (179) 179
biochemistry (176) 176
dna-damage (175) 175
gene expression regulation, neoplastic - drug effects (175) 175
carcinoma (174) 174
phosphorylation - drug effects (174) 174
medicine, research & experimental (173) 173
pathway (172) 172
cyclin-dependent kinases (171) 171
antineoplastic agents, phytogenic - pharmacology (170) 170
caspase 3 - metabolism (168) 168
cell division (167) 167
tumor cells, cultured (164) 164
cell movement - drug effects (162) 162
induction (161) 161
transfection (160) 160
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3115) 3115
Japanese (19) 19
Chinese (5) 5
German (2) 2
Russian (2) 2
French (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Journal of biological chemistry, ISSN 1083-351X, 2013, Volume 288, Issue 42, pp. 30320 - 30329
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0158963
... (5, 10, 15, 20 and 25 mg/ml) of MEAD for 24, 48 and 72 h and changes in cell morphology, cell cycle, apoptosis related protein and gene expression were studied... 
CYTOCHROME-C | QUERCETIN | ACTIVATION | MULTIDISCIPLINARY SCIENCES | PROSTATE-CANCER | MITOCHONDRIA | PROLIFERATION | FLAVONOIDS | MYRICETIN | INDUCTION | CASPASE CASCADE | Adenocarcinoma - pathology | Apoptosis - drug effects | Microscopy, Phase-Contrast | Plant Extracts - pharmacology | Humans | Caspase 3 - metabolism | Apoptosis - genetics | Membrane Potential, Mitochondrial - drug effects | Neoplasm Proteins - metabolism | MCF-7 Cells | Cell Cycle Checkpoints - genetics | Female | Adenocarcinoma - genetics | DNA Fragmentation - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Real-Time Polymerase Chain Reaction | Methanol | In Situ Nick-End Labeling | Up-Regulation - genetics | Cell Shape - drug effects | Up-Regulation - drug effects | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Cell Proliferation - drug effects | S Phase - drug effects | Phoeniceae - chemistry | Adenocarcinoma | Cell culture | Patient outcomes | Date palm | Breast cancer | Research | Antineoplastic agents | Gene expression | Statistics | Date | Antimitotic agents | Analysis | Health aspects | Apoptosis | Cytochrome | Cell proliferation | Flow cytometry | Bax protein | Bcl-2 protein | p53 Protein | Cytology | Indigenous plants | Biochemistry | Kinases | Cancer therapies | Cell morphology | Anticancer properties | Antioxidants | Mitochondria | Cell growth | Precision medicine | Cell cycle | Polyphenols | Membrane potential | Medical research | Statistical analysis | Caspase | Shrinkage | Flavonoids | Phytochemicals | FasL protein | Microscopy | Phase contrast | Alternative medicine | Annexin V | Synergistic effect | In vitro methods and tests | Prostate cancer
Journal Article
PloS one, ISSN 1932-6203, 2012, Volume 7, Issue 1, p. e28568
... proliferation and distorting fate-driven cell cycle exit. The identification of cell permeable small molecules that activate the G1/S checkpoint may therefore represent a broadly applicable and clinically effective strategy for the treatment of cancer... 
MULTIPLE-MYELOMA | BREAST-CANCER | TRANSLATIONAL REGULATION | UNFOLDED-PROTEIN RESPONSE | RETINOBLASTOMA PROTEIN | CYCLIN D1 | PHOSPHORYLATION | ER STRESS | MULTIDISCIPLINARY SCIENCES | ENDOPLASMIC-RETICULUM | CELL-CYCLE | Enzyme Activators - pharmacology | Cyclin D1 - metabolism | Paclitaxel - pharmacology | Endoplasmic Reticulum Stress - drug effects | Oligonucleotide Array Sequence Analysis | eIF-2 Kinase - metabolism | Humans | Retinoblastoma Protein - metabolism | DNA, Complementary - genetics | Transcriptome - drug effects | Transcriptome - genetics | Enzyme Activation - drug effects | Mice, Knockout | Animals | Drug Interactions | Signal Transduction - drug effects | Enzyme Activators - chemistry | Eukaryotic Initiation Factor-2 - metabolism | Mice | Phosphorylation - drug effects | Drug Evaluation, Preclinical | G1 Phase Cell Cycle Checkpoints - drug effects | S Phase Cell Cycle Checkpoints - drug effects | Cluster Analysis | Chemotherapy | Genetic aspects | Genetic translation | Phosphotransferases | Cancer | Ubiquitin | Phosphorylation | Biomedical research | Transcription | Laboratories | Genes | Multiple myeloma | Activation | Identification | Biology | Sleep apnea | Taxane | Kinases | Phosphatase | Anticancer properties | Proteins | Signal transduction | Paclitaxel | Cell cycle | Genetics | Initiation factor eIF-2 | Deoxyribonucleic acid--DNA | Medical research | Translation | Cyclin-dependent kinases | Translation initiation | Translation initiation factor 2 | Mode of action | Signaling | DNA microarrays | Mutation | Taxanes | Endoplasmic reticulum | Apoptosis | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 5, p. e98207
Recent studies have demonstrated that the anti-diabetic drug, metformin, can exhibit direct antitumoral effects, or can indirectly decrease tumor proliferation by improving insulin sensitivity... 
PROSTATE | OBESITY | ACTIVATED PROTEIN-KINASE | INHIBITION | INSULIN-RESISTANCE | MULTIDISCIPLINARY SCIENCES | IN-VIVO | GROWTH | AKT | AUTOPHAGY | TUMOR SUPPRESSORS | AMP-Activated Protein Kinases - metabolism | Oxidants - pharmacology | Hydrogen - pharmacology | Apoptosis - drug effects | Humans | Metformin - pharmacology | Enzyme Activation - drug effects | Neoplasm Proteins - metabolism | Breast Neoplasms - metabolism | Hypoglycemic Agents - pharmacology | Breast Neoplasms - pathology | Forkhead Transcription Factors - metabolism | Cell Line, Tumor | Female | Resting Phase, Cell Cycle - drug effects | Oxidative Stress - drug effects | Forkhead Box Protein O3 | G1 Phase Cell Cycle Checkpoints - drug effects | AMP-Activated Protein Kinases - genetics | Oxidative stress | Cancer cells | Cell cycle | Breast cancer | Metformin | Diabetes therapy | Apoptosis | Flow cytometry | Cell culture | Phosphorylation | Hydrogen peroxide | Bax protein | Bcl-2 protein | AKT protein | Superoxide dismutase | Biology | Activation | Kinases | Caspase-3 | Cancer therapies | Western blotting | Necrosis | Proteins | Signal transduction | Cell growth | Catalase | Penicillin | FOXO3 protein | G1 phase | Diabetes mellitus | Extracellular signal-regulated kinase | Caspase | MAP kinase | Pharmacology | Gene expression | Insulin | Zinc | Polymerase chain reaction | Cytometry | Molecular modelling | Cell number | Diabetes | Prostate | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2013, Volume 8, Issue 8, p. e71115
Renal cell carcinoma (RCC) is the sixth most common cancer in the US. While RCC is highly metastatic, there are few therapeutics options available for patients... 
ACTIVATED-RECEPTOR-ALPHA | THERAPY | METABOLISM | MECHANISM | MULTIDISCIPLINARY SCIENCES | C-MYC | IDENTIFICATION | PEROXISOME PROLIFERATORS | CARCINOMA | EPIDEMIOLOGY | PROGRESSION | Immunohistochemistry | Tyrosine - pharmacology | Cyclin D1 - metabolism | Kidney Neoplasms - genetics | Apoptosis - drug effects | Humans | Carcinoma, Renal Cell - genetics | Cell Survival - genetics | Apoptosis - genetics | Immunoblotting | Kidney Neoplasms - metabolism | G1 Phase - drug effects | Glycolysis - drug effects | Tyrosine - analogs & derivatives | Glycolysis - genetics | Glycolysis - physiology | RNA Interference | Deoxyglucose - pharmacology | Cell Cycle Checkpoints - genetics | G1 Phase - genetics | Cell Survival - physiology | Cell Line | Cell Survival - drug effects | PPAR alpha - antagonists & inhibitors | Carcinoma, Renal Cell - pathology | Cell Cycle Checkpoints - physiology | PPAR alpha - genetics | Glucose - pharmacology | Cyclin-Dependent Kinase 4 - metabolism | G1 Phase - physiology | Proto-Oncogene Proteins c-myc - metabolism | Carcinoma, Renal Cell - metabolism | Resting Phase, Cell Cycle - genetics | Cell Cycle Checkpoints - drug effects | Resting Phase, Cell Cycle - physiology | Cell Line, Tumor | Glucose - metabolism | Kidney Neoplasms - pathology | Resting Phase, Cell Cycle - drug effects | Oxazoles - pharmacology | Apoptosis - physiology | PPAR alpha - metabolism | Metabolomics | Energy metabolism | Nephrology | Syngeneic grafts | Toxicity | c-Myc protein | Cytotoxicity | Myc protein | Cyclin D1 | Cancer therapies | Cyclin-dependent kinase 4 | Metastases | Proteins | Allografts | Cell cycle | Xenografts | Oxidation | Inhibition | Internal medicine | siRNA | Metabolism | Patients | Fatty acids | Pathology | MicroRNAs | Kidney cancer | Proteomics | Glycolysis | VHL protein | Regulatory proteins | Clear cell-type renal cell carcinoma | Cancer | Apoptosis | Kidney transplantation
Journal Article
PloS one, ISSN 1932-6203, 2015, Volume 10, Issue 7, p. e0133349
.... However, the antitumor effects of metformin on ESCC and the mechanisms underlying its cell cycle regulation remain elusive... 
CANCER-CELLS | PROSTATE | APOPTOSIS | CISPLATIN | ANGIOGENESIS | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | LIVER | PROLIFERATION | INDUCTION | Cyclin D1 - metabolism | AMP-Activated Protein Kinases - metabolism | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Male | Esophageal Neoplasms - pathology | Cyclin-Dependent Kinase Inhibitor p27 - metabolism | Esophageal Neoplasms - metabolism | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Cell Survival - drug effects | Metformin - pharmacology | Tumor Suppressor Protein p53 - metabolism | Enzyme Activation - drug effects | Blotting, Western | Hypoglycemic Agents - pharmacology | Xenograft Model Antitumor Assays | Animals | Carcinoma, Squamous Cell - drug therapy | Tumor Burden - drug effects | Mice, Nude | Cell Line, Tumor | Resting Phase, Cell Cycle - drug effects | Cell Proliferation - drug effects | G1 Phase Cell Cycle Checkpoints - drug effects | Esophageal Neoplasms - drug therapy | Diabetics | Squamous cell carcinoma | Growth | Cell cycle | Metformin | Tumor proteins | Health aspects | Esophageal cancer | Flow cytometry | Regulations | p53 Protein | Colorectal cancer | Kinases | Epidemiology | Anticancer properties | Angiogenesis | Cell activation | Cell growth | Gastroenterology | Xenografts | Tumorigenesis | Inhibition | Growth factors | G1 phase | Esophageal carcinoma | Enzymes | Adenosine | Diabetes mellitus | Cyclin-dependent kinases | Health risks | Risk reduction | Cell division | Metabolism | Esophagus | Cyclin-dependent kinase inhibitor p21 | Hospitals | Cyclin-dependent kinase inhibitor p27 | Antitumor activity | Hypoxia | Cancer
Journal Article
PloS one, ISSN 1932-6203, 2015, Volume 10, Issue 9, pp. e0138616 - e0138616
Cell cycle checkpoint intervention is an effective therapeutic strategy for cancer when applied to patients predisposed to respond and the treatment is well-tolerated... 
BREAST-CANCER | ANEUPLOIDY | KINETOCHORES | EVOLUTION | MICROTUBULES | MULTIDISCIPLINARY SCIENCES | CDK4/6 INHIBITION | MECHANISMS | DISCOVERY | SPINDLE-ASSEMBLY CHECKPOINT | CHROMOSOMAL INSTABILITY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Phosphorylation | Intestine, Small - pathology | Apoptosis - drug effects | Protein-Tyrosine Kinases - metabolism | Humans | Transplantation, Heterologous | Cell Cycle Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - genetics | RNA Interference | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Bone Marrow Cells - drug effects | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Cell Survival - drug effects | Bone Marrow Cells - cytology | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Rats | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Mice, SCID | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Animals | Mitosis - drug effects | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Kinase Inhibitors - toxicity | Breast Neoplasms - diagnosis | Cell Proliferation - drug effects | Mice | Pyridines - pharmacology | Histones - metabolism | G1 Phase Cell Cycle Checkpoints - drug effects | Bone Marrow Cells - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | RNA, Small Interfering - metabolism | Physiological aspects | Genetic aspects | Research | Mitosis | Protein kinases | Toxicity | Body weight | Cytotoxicity | Oncology | Body weight loss | Catalytic activity | Kinases | Cancer therapies | Cyclin-dependent kinase 4 | Genomic instability | Proteins | Metaphase | Cell cycle | Bone marrow | Physiology | Bioindicators | Inhibition | Pretreatment | Catalysis | Drug therapy | Product safety | Chromosomes | Pharmaceutical sciences | Neutropenia | Stability | Research & development--R&D | Tumor cells | Cell division | Breast cancer | Pharmacology | Hypotheses | Inhibitors | Biomarkers | Safety research | Anaphase | Apoptosis | Tumors | Cancer | Index Medicus | Research & development | R&D
Journal Article